


CLINICAL TRIAL

XIRIUS - NCT03116113



Research

A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

Rare Eye Disease concerned by the trial :
X-linked Retinitis Pigmentosa

Status of the trial : recruiting
Orphan drug recognition : No

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date : 01/08/2017



Inclusion closing date : 31/01/2018

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Manchester University Hospitals NHS Foundation Trust

Manchester Royal Eye Hospital
Oxford Road
Manchester M13 9WL
UK

[Contact details](#)



Principal investigator name :


Prof. Paulo Stanga



Other investigators :

None

Funder type : Drug company - Industry



[More informations](#)